RNA-Seq differentiates the tumour (human) transcriptional response to cediranib from the host (mouse).

<p>Gene Set Enrichment Analysis (GSEA) reveals significant enrichment of (A) hypoxia and (B) cell cycle associated signatures in tumour genes differentially regulated in response to cediranib dosed at 6 mg/kg once daily for 4 days (** indicates gene sets enriched with <i>p</i><0.001, FDR <i>q</i><0.05 and FWER <i>p</i><0.1; * indicates gene sets enriched with <i>p</i><0.001 and FDR <i>q</i><0.05). GSEA-defined “Leading Edge” genes most frequently included in (C) hypoxia-associated gene sets and up-regulated in response to cediranib include CA9, HK2 and VEGFA. Leading edge cell cycle associated genes are given in (D). (E) Ingenuity Pathway Analysis (IPA) highlights functions significantly enriched (<i>p</i><1×10⁻⁵) amongst host genes differentially regulated in response to cediranib. For both GSEA and IPA, genes achieving a log₂ fold change magnitude>1 and <i>p</i><0.1 were defined as differentially regulated. <i>n</i> = 2 in treated and control groups; a positive fold change indicates genes up-regulated in response to cediranib, and <i>vice versa</i>.